Compare MYO & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYO | DARE |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 33.4M |
| IPO Year | 2017 | 2014 |
| Metric | MYO | DARE |
|---|---|---|
| Price | $1.46 | $2.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.67 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.1M | 228.4K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,000,000.00 | $2,807,885.00 |
| Revenue This Year | $9.10 | $2,115.12 |
| Revenue Next Year | $13.59 | $122.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40814.79 | N/A |
| 52 Week Low | $0.61 | $1.27 |
| 52 Week High | $2.83 | $9.19 |
| Indicator | MYO | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 64.05 | 43.02 |
| Support Level | $0.76 | $1.94 |
| Resistance Level | N/A | $2.01 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 80.65 | 29.79 |
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.